On this episode of Investor Connect, Hall T. Martin welcomes Ronan O’Hagan, President & CEO of Bectas Therapeutics Inc., a groundbreaking biotech company focused on revolutionizing precision oncology. Based in Houston, TX, Bectas Therapeutics is committed to developing cancer therapies for people living with cancer who do not benefit from the existing standard-of-care treatments. O’Hagan discusses Bectas Therapeutics’ precision cancer therapies that leverage unique insights from human cancer patients to develop First in Class therapies accompanied by blood-based biomarkers. He emphasizes the significance of clinical proof of concept and highlights the opportunity Bectas has to bring benefit to patients and to rapidly create value with potential early exits for investors.